Regeneron Pharmaceuticals (REGN)

• Market cap: $74.9B
• 1 day: -1.68%
• 5 days: 1.84%
• 1 month: -7.90%
• 3 months: -31.72%
• 6 months: -37.22%
• Year to date: -4.70%
• 1 year: -26.64%
• 5 years: 76.60%
• 10 years: 61.85%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 14,176

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 138 | Existing positions closed: 69

17% more repeat investments, than reductions

Existing positions increased: 529 | Existing positions reduced: 453

4% more funds holding

Funds holding: 1,309 [Q2] → 1,360 (+51) [Q3]

5% less capital invested

Capital invested by funds: $109B [Q2] → $104B (-$5.03B) [Q3]

3.43% less ownership

Funds ownership: 95.63% [Q2] → 92.2% (-3.43%) [Q3]

18% less funds holding in top 10

Funds holding in top 10: 28 [Q2] → 23 (-5) [Q3]

23% less call options, than puts

Call options by funds: $1.45B | Put options by funds: $1.88B

Research analyst outlook

17 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $165 76% downside
• Avg. target: $975 43% upside
• High target: $1,215 78% upside

17 analyst ratings

• positive: 12 71%
• neutral: 4 24%
• negative: 1 6%

UBS Trung Huynh 40% 1-year accuracy 2 / 5 met price target	8% upside $738	Neutral Downgraded	16 Jan 2025
Citigroup Geoff Meacham 41% 1-year accuracy 11 / 27 met price target	17% upside $795	Neutral Maintained	14 Jan 2025
Wells Fargo Mohit Bansal 31% 1-year accuracy 8 / 26 met price target	32% upside $900	Overweight Maintained	10 Jan 2025
Truist Securities Srikripa Devarakonda 30% 1-year accuracy 10 / 33 met price target	47% upside $1,004	Buy Maintained	8 Jan 2025
Bernstein William Pickering 14% 1-year accuracy 1 / 7 met price target	57% upside $1,070	Outperform Maintained	7 Jan 2025